Reviewed,
UniProtKB/Swiss-Prot P45983 (MK08_HUMAN)
Last modified
November 25, 2008.
Version 98.
History...
Clusters with 100%,
90%,
50% identity |
Documents (8) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Recommended name: Mitogen-activated protein kinase 8 EC=2.7.11.24 Alternative name(s): Stress-activated protein kinase JNK1 c-Jun N-terminal kinase 1 JNK-46 | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo |
Protein attributes
| Sequence length | 427 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is not processed. |
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | Responds to activation by environmental stress and pro-inflammatory cytokines by phosphorylating a number of transcription factors, primarily components of AP-1 such as JUN, JDP2 and ATF2 and thus regulates AP-1 transcriptional activity. In T-cells, JNK1 and JNK2 are required for polarized differentiation of T-helper cells into Th1 cells By similarity. Phosphorylates heat shock factor protein 4 (HSF4). JNK1 isoforms display different binding patterns: beta-1 preferentially binds to c-Jun, whereas alpha-1, alpha-2, and beta-2 have a similar low level of binding to both c-Jun or ATF2. However, there is no correlation between binding and phosphorylation, which is achieved at about the same efficiency by all isoforms. |
| Catalytic activity | ATP + a protein = ADP + a phosphoprotein. |
| Cofactor | Magnesium. |
| Enzyme regulation | Activated by threonine and tyrosine phosphorylation by either of two dual specificity kinases, MAP2K4 and MAP2K7. Inhibited by dual specificity phosphatases, such as DUSP1. |
| Subunit structure | Binds to at least four scaffolding proteins, MAPK8IP1/JIP-1, MAPK8IP2/JIP-2, MAPK8IP3/JIP-3/JSAP1 and SPAG9/MAPK8IP4/JIP-4. These proteins also bind other components of the JNK signaling pathway. Interacts with TP53 and WWOX. Interacts with JAMP. Forms a complex with MAPK8IP1 and RGNEF By similarity. |
| Domain | The TXY motif contains the threonine and tyrosine residues whose phosphorylation activates the MAP kinases. |
| Post-translational modification | Dually phosphorylated on Thr-183 and Tyr-185, which activates the enzyme. |
| Sequence similarities | Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. MAP kinase subfamily. Contains 1 protein kinase domain. |
Ontologies
Keywords | |
|---|---|
| Coding sequence diversity | Alternative splicing Polymorphism |
| Ligand | ATP-binding Nucleotide-binding |
| Molecular function | Kinase Serine/threonine-protein kinase Transferase |
| PTM | Phosphoprotein |
| Technical term | 3D-structure |
Gene Ontology (GO) | |
| Biological process | JUN phosphorylation Inferred from direct assay. Source: MGI activation of pro-apoptotic gene productsInferred from Experiment. Source: Reactome cell motionTraceable author statement. Source: ProtInc negative regulation of apoptosisInferred from direct assay. Source: MGI response to UVInferred from direct assay. Source: MGI response to stress Ref.1Traceable author statement. Source: ProtInc |
| Cellular component | cytosol Inferred from Experiment. Source: Reactome |
| Molecular function | ATP binding Inferred from electronic annotation. Source: InterPro JUN kinase activity Ref.2Inferred from direct assay. Source: UniProtKB protein bindingInferred from physical interaction. Source: UniProtKB |
| Complete GO annotation... | |
Binary interactions
With | Entry | #Exp. | IntAct | Notes |
|---|---|---|---|---|
| ATF2 | P15336 | 1 | EBI-288687,EBI-1170906 | |
| JUN | P05412 | 2 | EBI-286483,EBI-852823 | |
| JUN | P05412 | 2 | EBI-288687,EBI-852823 | |
| MAP2K4 | P45985 | 1 | EBI-286483,EBI-447868 | |
| MAP2K7 | O14733-2 | 2 | EBI-286483,EBI-492627 | |
| Mapk8ip1 | Q9WVI9-1 | 1 | EBI-286483,EBI-288461 | From a different organism. |
Alternative products
| This entry describes 4 isoforms produced by alternative splicing. [Align] [Select] | ||||||
| Isoform 2 (identifier: P45983-1) Also known as: JNK1-alpha-2; This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform 1 (identifier: P45983-2) Also known as: JNK1-alpha-1; The sequence of this isoform differs from the canonical sequence as follows: 380-427: GAAVINGSQHPSSSSSVNDVSSMSTDPTLASDTDSSLEAAAGPLGCCR → AQVQQ | ||||||
| Isoform 3 (identifier: P45983-3) Also known as: JNK1-beta-1; The sequence of this isoform differs from the canonical sequence as follows: 208-208: L → I 219-230: VCHKILFPGRDY → IKGGVLFPGTDH 380-427: GAAVINGSQHPSSSSSVNDVSSMSTDPTLASDTDSSLEAAAGPLGCCR → AQVQQ | ||||||
| Isoform 4 (identifier: P45983-4) Also known as: JNK1-beta-2; The sequence of this isoform differs from the canonical sequence as follows: 208-208: L → I 219-230: VCHKILFPGRDY → IKGGVLFPGTDH |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecule processing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 427 | 427 | Mitogen-activated protein kinase 8 | PRO_0000186262 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Regions | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Domain | 26 – 321 | 296 | Protein kinase | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Nucleotide binding | 32 – 40 | 9 | ATP By similarity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Motif | 183 – 185 | 3 | TXY | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sites | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Active site | 151 | 1 | Proton acceptor By similarity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Binding site | 55 | 1 | ATP By similarity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amino acid modifications | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 183 | 1 | Phosphothreonine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 185 | 1 | Phosphotyrosine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 255 | 1 | Phosphothreonine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 258 | 1 | Phosphothreonine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 259 | 1 | Phosphotyrosine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 357 | 1 | Phosphotyrosine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 367 | 1 | Phosphothreonine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Modified residue | 377 | 1 | Phosphoserine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Natural variations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 208 | 1 | L → I in isoform 3 and isoform 4. | VSP_004831 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 219 – 230 | 12 | VCHKI…PGRDY → IKGGVLFPGTDH in isoform 3 and isoform 4. | VSP_004832 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 380 – 427 | 48 | GAAVI…LGCCR → AQVQQ in isoform 1 and isoform 3. | VSP_004833 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Natural variant | 171 | 1 | G → S in a renal clear cell carcinoma sample; somatic mutation. | VAR_042258 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Natural variant | 177 | 1 | G → R in a glioblastoma multiforme sample; somatic mutation. | VAR_042259 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Experimental info | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 183 | 1 | T → A: Phosphorylation blocked | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 185 | 1 | Y → F: Phosphorylation blocked | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Secondary structure | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Helix Strand Turn | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 10 – 15 | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 18 – 23 | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 26 – 45 | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Turn | 46 – 49 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 50 – 59 | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 64 – 79 | 16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 88 – 92 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Turn | 98 – 100 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 105 – 109 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 112 – 114 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 115 – 118 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 125 – 143 | 19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Turn | 144 – 146 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Turn | 154 – 156 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 157 – 159 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta strand | 165 – 167 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 194 – 197 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 206 – 220 | 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 230 – 241 | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 246 – 250 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 254 – 260 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 271 – 274 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 277 – 279 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 288 – 301 | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 306 – 308 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 312 – 317 | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Turn | 319 – 321 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 322 – 324 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 327 – 330 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Helix | 351 – 361 | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sequences
| ||||||||||||||||||||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain." Derijard B., Hibi M., Wu I.-H., Barrett T., Su B., Deng T., Karin M., Davis R.J. Cell 76:1025-1037(1994) [PubMed: 8137421] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA]. Tissue: Fetal brain. |
| [2] | "Selective interaction of JNK protein kinase isoforms with transcription factors." Gupta S., Barrett T., Whitmarsh A.J., Cavanagh J., Sluss H.K., Derijard B., Davis R.J. EMBO J. 15:2760-2770(1996) [PubMed: 8654373] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA], ALTERNATIVE SPLICING. Tissue: Brain. |
| [3] | "Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms." Derijard B., Raingeaud J., Barrett T., Wu I.-H., Han J., Ulevitch R.J., Davis R.J. Science 267:682-685(1995) [PubMed: 7839144] [Abstract] Cited for: MUTAGENESIS. |
| [4] | "Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7." Fleming Y., Armstrong C.G., Morrice N., Paterson A., Goedert M., Cohen P. Biochem. J. 352:145-154(2000) [PubMed: 11062067] [Abstract] Cited for: REGULATION BY MAP2K4 AND MAP2K7, COFACTOR. |
| [5] | "JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis." Chang N.-S., Doherty J., Ensign A. J. Biol. Chem. 278:9195-9202(2003) [PubMed: 12514174] [Abstract] Cited for: INTERACTION WITH WWOX AND TP53. |
| [6] | "Characterization of a novel human sperm-associated antigen 9 (SPAG9) having structural homology with c-Jun N-terminal kinase-interacting protein." Jagadish N., Rana R., Selvi R., Mishra D., Garg M., Yadav S., Herr J.C., Okumura K., Hasegawa A., Koyama K., Suri A. Biochem. J. 389:73-82(2005) [PubMed: 15693750] [Abstract] Cited for: INTERACTION WITH SPAG9. |
| [7] | "Association and regulation of heat shock transcription factor 4b with both extracellular signal-regulated kinase mitogen-activated protein kinase and dual-specificity tyrosine phosphatase DUSP26." Hu Y., Mivechi N.F. Mol. Cell. Biol. 26:3282-3294(2006) [PubMed: 16581800] [Abstract] Cited for: FUNCTION, INTERACTION WITH HSF4. |
| [8] | "Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer." Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.M. Comb M.J.Cell 131:1190-1203(2007) [PubMed: 18083107] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-185, MASS SPECTROMETRY. Tissue: Lung. |
| [9] | "Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra." Yu L.-R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D. J. Proteome Res. 6:4150-4162(2007) [PubMed: 17924679] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-255; THR-258; TYR-259; TYR-357 AND THR-367, MASS SPECTROMETRY. Tissue: Epithelium. |
| [10] | "Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry." Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R., Keri G., Wehland J., Daub H. Mol. Cell. Proteomics 6:537-547(2007) [PubMed: 17192257] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-183 AND TYR-185, MASS SPECTROMETRY. |
| [11] | "Phosphorylation of two eukaryotic transcription factors, Jun dimerization protein 2 and activation transcription factor 2, in Escherichia coli by Jun N-terminal kinase 1." Murata T., Shinozuka Y., Obata Y., Yokoyama K.K. Anal. Biochem. 376:115-121(2008) [PubMed: 18307971] [Abstract] Cited for: FUNCTION IN PHOSPHORYLATION OF JDP2. |
| [12] | "A quantitative atlas of mitotic phosphorylation." Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., Elledge S.J., Gygi S.P. Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008) [PubMed: 18669648] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCA |

Clusters with